Health Canada has proposed regulations that will amend the Food and Drug Regulations to allow for importation of drugs that have not yet received regulatory approval from Health Canada. The new regulations will provide access to drugs that address an urgent public health need provided they have been approved in the United States, the European Union, or Switzerland. "Urgent public health need" is not a defined term in the regulations, but Health Canada identified treatment of opioid use disorder as a current example of an urgent need.
This scheme does not replace existing programs that provide access to drugs that have not received regulatory approval, such as the Special Access Programme or a Clinical Trial Application. Unlike those programs, the new regulations will only allow importation after a public health official notifies the minister of an urgent public health need for the drug.
While importation and sale of these drugs will be exempt from many aspects of the Food and Drug Regulations, certain reporting and record-keeping obligations will be imposed. Further, healthcare institutions will be required to report serious adverse events to Health Canada. This is the first time regulations have required adverse event reporting by healthcare institutions. The authority to do so comes from not-yet-in-force provisions of the Protecting Canadians from Unsafe Drugs Act [Vanessa's Law].
The proposed regulations will not come into force until the necessary provisions in Vanessa's Law are in force. In the meantime, Health Canada is taking preparatory steps, including developing guidance and canvasing public health officials to populate an initial list of drugs.
Link:
The proposed regulations and Regulatory Impact Analysis Statement can be found here.
About Norton Rose Fulbright Canada LLP
Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.
Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.
Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.
For more information about Norton Rose Fulbright, see nortonrosefulbright.com/legal-notices.
Law around the world
nortonrosefulbright.com
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
